Discover open access scientific publications

Search, annotate, share and cite publications

Publications by E Wattel

Lenalidomide With or Without Erythropoietin in Transfusion-Dependent Erythropoiesis-Stimulating Agent-Refractory Lower-Risk MDS Without 5q Deletion

Leukemia

English

Molecular and Cellular Aspects of HTLV-1 Associated Leukemogenesis in Vivo

English

Related publications

Long-Term Outcome of Anemic Lower-Risk Myelodysplastic Syndromes Without 5q Deletion Refractory to or Relapsing After Erythropoiesis-Stimulating Agents

English

Extended Survival and Reduced Risk of AML Progression in Erythroid-Responsive Lenalidomide-Treated Patients With Lower-Risk Del(5q) MDS

English

A Critical Role for Phosphatase Haplodeficiency in the Selective Suppression of Deletion 5q MDS by Lenalidomide

Proceedings of the National Academy of Sciences of the United States of America

Multidisciplinary

2009

English

Unusual Clonal Evolution Involving 5q in a Case of Myelodysplastic Syndrome With Deletion 5q 31 Treated With Lenalidomide

Haematologica

Hematology

2008

English

PUK32 Lower Case Mix Adjusters Are Associated With Lower Erythropoiesis-Stimulating Agent (ESA) and Other Bundled Costs

English

The Effect of Lenalidomide on Health-Related Quality of Life in Patients With Lower-Risk Non-Del(5q) Myelodysplastic Syndromes: Results From the MDS-005 Study

Clinical Lymphoma, Myeloma and Leukemia

English

Familial Clubfoot With or Without Associated Lower Limb Anomalies

2020

English

Patients With Del(5q) MDS Who Fail to Achieve Sustained Erythroid or Cytogenetic Remission After Treatment With Lenalidomide Have an Increased Risk for Clonal Evolution and AML Progression

English

The Role of Ineffective Erythropoiesis in Non-Transfusion-Dependent Thalassemia

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by E Wattel

Lenalidomide With or Without Erythropoietin in Transfusion-Dependent Erythropoiesis-Stimulating Agent-Refractory Lower-Risk MDS Without 5q Deletion

Molecular and Cellular Aspects of HTLV-1 Associated Leukemogenesis in Vivo

Related publications

Long-Term Outcome of Anemic Lower-Risk Myelodysplastic Syndromes Without 5q Deletion Refractory to or Relapsing After Erythropoiesis-Stimulating Agents

Extended Survival and Reduced Risk of AML Progression in Erythroid-Responsive Lenalidomide-Treated Patients With Lower-Risk Del(5q) MDS

A Critical Role for Phosphatase Haplodeficiency in the Selective Suppression of Deletion 5q MDS by Lenalidomide

Unusual Clonal Evolution Involving 5q in a Case of Myelodysplastic Syndrome With Deletion 5q 31 Treated With Lenalidomide

PUK32 Lower Case Mix Adjusters Are Associated With Lower Erythropoiesis-Stimulating Agent (ESA) and Other Bundled Costs

The Effect of Lenalidomide on Health-Related Quality of Life in Patients With Lower-Risk Non-Del(5q) Myelodysplastic Syndromes: Results From the MDS-005 Study

Familial Clubfoot With or Without Associated Lower Limb Anomalies

Patients With Del(5q) MDS Who Fail to Achieve Sustained Erythroid or Cytogenetic Remission After Treatment With Lenalidomide Have an Increased Risk for Clonal Evolution and AML Progression

The Role of Ineffective Erythropoiesis in Non-Transfusion-Dependent Thalassemia